[Nadolol + bendroflumethiazide in a fixed combination and in sequential administration. Experimental research on antihypertensive efficacy and tolerability].
Del Re
M L
ML
Ricci
A
A
Abate
G
G
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D001539:Bendroflumethiazide / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D011412:Propanolamines / Q000008:administration & dosage* / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D004338:Drug Combinations; D011412:Propanolamines; D009248:Nadolol; D001539:Bendroflumethiazide
Nadololo + bendroflumetiazide in associazione fissa ed in somministrazione sequenziale. Ricerche sperimentali sull'efficacia antiipertensiva e la tollerabilità.